Bone marrow aspirate concentrate (BMAC) is increasingly used as a regenerative therapy for musculoskeletal pathological conditions despite limited evidence-based support.
Hypothesis:
BMAC will prove feasible, safe, and efficacious for the treatment of pain due to mild to moderate degenerative joint disease of the knee.
Study Design:
Randomized controlled trial; Level of evidence, 2.
Methods:
In this prospective, single-blind, placebo-controlled trial, 25 patients with bilateral knee pain from bilateral osteoarthritis were randomized to receive BMAC into one knee and saline placebo into the other. Fifty-two milliliters of bone marrow was aspirated from the iliac crests and concentrated in an automated centrifuge. The resulting BMAC was combined with platelet-poor plasma for an injection into the arthritic knee and was compared with a saline injection into the contralateral knee, thereby utilizing each patient as his or her own control. Safety outcomes, pain relief, and function as measured by Osteoarthritis Research Society International (OARSI) measures and the visual analog scale (VAS) score were tracked initially at 1 week, 3 months, and 6 months after the procedure.
Results:
There were no serious adverse events from the BMAC procedure. OARSI Intermittent and Constant Osteoarthritis Pain and VAS pain scores in both knees decreased significantly from baseline at 1 week, 3 months, and 6 months (P ≤ .019 for all). Pain relief, although dramatic, did not differ significantly between treated knees (P > .09 for all).
Conclusion:
Early results show that BMAC is safe to use and is a reliable and viable cellular product. Study patients experienced a similar relief of pain in both BMAC- and saline-treated arthritic knees. Further study is required to determine the mechanisms of action, duration of efficacy, optimal frequency of treatments, and regenerative potential.
BannuruRRMcAlindonTESullivanMCWongJBKentDMSchmidCH.Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials. Ann Intern Med. 2015;163(5):365-372.
3.
BannuruRRSchmidCHKentDMVaysbrotEEWongJBMcAlindonTE.Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54.
4.
BondMDavisALohmanderSHawkerG.Responsiveness of the OARSI-OMERACT osteoarthritis pain and function measures. Osteoarthritis Cartilage. 2012;20(6):541-547.
5.
BudaRVanniniFCavalloMGrigoloBCenacchiAGianniniS.Osteochondral lesions of the knee: a new one-step repair technique with bone-marrow-derived cells. J Bone Joint Surg Am. 2010;92Suppl 2:2-11.
6.
CaplanAI.Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007;213(2):341-347.
7.
CaplanAICorreaD.The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15.
8.
CentenoCPittsJAl-SayeghHFreemanM.Efficacy of autologous bone marrow concentrate for knee osteoarthritis with and without adipose graft. Biomed Res Int. 2014;2014:370621.
9.
Centers for Disease Control and Prevention. Cost of hospital discharges with common hospital operating room procedures in nonfederal community hospitals, by age and selected principal procedure: United States, selected years 2000–2012. Table 105. Available at: http://www.cdc.gov/nchs/data/hus/2014/105.pdf. Accessed November 4, 2015.
10.
ChahlaJDeanCSMoatsheGPascual-GarridoCSerra CruzRLaPradeRF.Concentrated bone marrow aspirate for the treatment of chondral injuries and osteoarthritis of the knee: a systematic review of outcomes. Orthop J Sports Med. 2016;4(1):23259671 15625481.
11.
ChenFHTuanRS.Mesenchymal stem cells in arthritic diseases. Arthritis Res Ther. 2008;10(5):223.
12.
ChengNCEstesBTAwadHAGuilakF.Chondrogenic differentiation of adipose-derived adult stem cells by a porous scaffold derived from native articular cartilage extracellular matrix. Tissue Eng Part A. 2009;15(2):231-241.
13.
ChuCR.The challenge and the promise of bone marrow cells for human cartilage repair. Cartilage. 2015;6(Suppl 2):36S-45S.
14.
ColemanCMCurtinCBarryFPO’FlathartaCMurphyJM.Mesenchymal stem cells and osteoarthritis: remedy or accomplice?Hum Gene Ther. 2010;21(10):1239-1250.
15.
DavatchiFAbdollahiBSMohyeddinMShahramFNikbinB.Mesenchymal stem cell therapy for knee osteoarthritis: preliminary report of four patients. Int J Rheum Dis. 2011;14(2):211-215.
16.
EseonuOIDe BariC.Homing of mesenchymal stem cells: mechanistic or stochastic? Implications for targeted delivery in arthritis. Rheumatology (Oxford). 2015;54(2):210-218.
17.
FilardoGKonEPereira RuizMT. Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: single- versus double-spinning approach. Knee Surg Sports Traumatol Arthrosc. 2012;20(10):2082-2091.
GoncalvesRSMeirelesACGilJNCavalheiroLMRosadoJOCabriJ.Responsiveness of Intermittent and Constant Osteoarthritis Pain (ICOAP) after physical therapy for knee osteoarthritis. Osteoarthritis Cartilage. 2012;20(10):1116-1119.
21.
GormeliGGormeliCAAtaogluBColakCAslanturkOErtemK. Multiple PRP injections are more effective than single injections and hyaluronic acid in knees with early osteoarthritis: a randomized, double-blind, placebo-controlled trial [published online August 2, 2015]. Knee Surg Sports Traumatol Arthrosc. doi:10.1007/s00167-015-3705-6.
22.
HamOLeeCYKimR. Therapeutic potential of differentiated mesenchymal stem cells for treatment of osteoarthritis. Int J Mol Sci. 2015;16(7):14961-14978.
23.
HatsushikaDMunetaTHorieMKogaHTsujiKSekiyaI.Intraarticular injection of synovial stem cells promotes meniscal regeneration in a rabbit massive meniscal defect model. J Orthop Res. 2013;31(9):1354-1359.
24.
HawkerGADavisAMFrenchMR. Development and preliminary psychometric testing of a new OA pain measure: an OARSI/OMERACT initiative. Osteoarthritis Cartilage. 2008;16(4):409-414.
25.
HawkerGAStewartLFrenchMR. Understanding the pain experience in hip and knee osteoarthritis: an OARSI/OMERACT initiative. Osteoarthritis Cartilage. 2008;16(4):415-422.
26.
HegdeVShonugaOEllisS. A prospective comparison of 3 approved systems for autologous bone marrow concentration demonstrated nonequivalency in progenitor cell number and concentration. J Orthop Trauma. 2014;28(10):591-598.
27.
HernigouPBeaujeanF.Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res. 2002;405:14-23.
28.
HernigouPPoignardABeaujeanFRouardH.Percutaneous autologous bone-marrow grafting for nonunions: influence of the number and concentration of progenitor cells. J Bone Joint Surg Am. 2005;87(7):1430-1437.
29.
HuebertRCRakelaJ.Cellular therapy for liver disease. Mayo Clin Proc. 2014;89(3):414-424.
30.
JoCHLeeYGShinWH. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014;32(5):1254-1266.
31.
KanayaADeieMAdachiNNishimoriMYanadaSOchiM.Intra-articular injection of mesenchymal stromal cells in partially torn anterior cruciate ligaments in a rat model. Arthroscopy. 2007;23(6):610-617.
32.
KimJDLeeGWJungGH. Clinical outcome of autologous bone marrow aspirates concentrate (BMAC) injection in degenerative arthritis of the knee. Eur J Orthop Surg Traumatol. 2014;24(8):1505-1511.
33.
KimYSChoiYJKohYG.Mesenchymal stem cell implantation in knee osteoarthritis: an assessment of the factors influencing clinical outcomes. Am J Sports Med. 2015;43(9):2293-2301.
34.
KimYSChoiYJLeeSW. Assessment of clinical and MRI outcomes after mesenchymal stem cell implantation in patients with knee osteoarthritis: a prospective study [published online August 28, 2015]. Osteoarthritis Cartilage. doi:10.1016/j.joca.2015.08.009.
35.
KimYSChoiYJSuhDS. Mesenchymal stem cell implantation in osteoarthritic knees: is fibrin glue effective as a scaffold?Am J Sports Med. 2015;43(1):176-185.
36.
KimYSKwonORChoiYJSuhDSHeoDBKohYG.Comparative matched-pair analysis of the injection versus implantation of mesenchymal stem cells for knee osteoarthritis. Am J Sports Med. 2015;43(11):2738-2746.
37.
KohYGChoiYJKwonSKKimYSYeoJE.Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2015;23(5):1308-1316.
KonEFilardoGDrobnicM. Non-surgical management of early knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2012;20(3):436-449.
40.
KurodaKKabataTHayashiK. The paracrine effect of adipose-derived stem cells inhibits osteoarthritis progression. BMC Musculoskelet Disord. 2015;16(1):236.
41.
KurodaRIshidaKMatsumotoT. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. Osteoarthritis Cartilage. 2007;15(2):226-231.
42.
LeeASEllmanMBYanD. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene. 2013;527(2):440-447.
43.
MendicinoMBaileyAMWonnacottKPuriRKBauerSR.MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell. 2014;14(2):141-145.
44.
MoretonBJWheelerMWalshDALincolnNB.Rasch analysis of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale. Osteoarthritis Cartilage. 2012;20(10):1109-1115.
45.
MurphyLSchwartzTAHelmickCG. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008;59(9):1207-1213.
46.
O’CearbhaillEDNgKSKarpJM.Emerging medical devices for minimally invasive cell therapy. Mayo Clin Proc. 2014;89(2):259-273.
47.
OrozcoLMunarASolerR. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. Transplantation. 2013;95(12):1535-1541.
48.
OrozcoLMunarASolerR. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: two-year follow-up results. Transplantation. 2014;97(11):e66-e68.
49.
OstermanCMcCarthyMBCoteMP. Platelet-rich plasma increases anti-inflammatory markers in a human coculture model for osteoarthritis. Am J Sports Med. 2015;43(6):1474-1484.
50.
PatelSDhillonMSAggarwalSMarwahaNJainA.Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med. 2013;41(2):356-364.
51.
PocockSJSimonR.Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103-115.
52.
SampsonSBotto-van BemdenAAufieroD.Autologous bone marrow concentrate: review and application of a novel intra-articular orthobiologic for cartilage disease. Phys Sportsmed. 2013;41(3):7-18.
53.
SampsonSReedMSilversHMengMMandelbaumB.Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil. 2010;89(12):961-969.
54.
SanchezMFizNAzofraJ. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy. 2012;28(8):1070-1078.
55.
SekiyaIOjimaMSuzukiS. Human mesenchymal stem cells in synovial fluid increase in the knee with degenerated cartilage and osteoarthritis. J Orthop Res. 2012;30(6):943-949.
56.
Taylor-WeinerHGraff ZivinJ.Medicine’s Wild West: unlicensed stem-cell clinics in the United States. N Engl J Med. 2015;373(11):985-987.
57.
TerzicANelsonTJ.Regenerative medicine primer. Mayo Clin Proc. 2013;88(7):766-775.
58.
TurnerLG.Federal regulatory oversight of US clinics marketing adipose-derived autologous stem cell interventions: insights from 3 new FDA draft guidance documents. Mayo Clin Proc. 2015;90(5):567-571.
59.
VangsnessCTJrFarrJ2ndBoydJDellaeroDTMillsCRLeRoux-WilliamsM.Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. J Bone Joint Surg Am. 2014;96(2):90-98.
60.
VeronesiFGiavaresiGTschonMBorsariVNicoli AldiniNFiniM.Clinical use of bone marrow, bone marrow concentrate, and expanded bone marrow mesenchymal stem cells in cartilage disease. Stem Cells Dev. 2013;22(2):181-192.
61.
ZhongWSumitaYOhbaS. In vivo comparison of the bone regeneration capability of human bone marrow concentrates vs. platelet-rich plasma. PLoS One. 2012;7(7):e40833.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
